Quality Programs, Accreditations

Camtech Laboratory participated in the External Quality Assessment Schemes (EQAS) and Proficiency Testing (PT) programs:

• Royal College of Pathologists Australia (RCPA)
• College of American Pathologists (CAP)

Clinical Molecular Testing Services

Cervical Cancer Screening

[Click Here] to download Camtech Lab Request Form for Cervical Cancer Screening

BD Onclarity™ HPV Assay

The BD Onclarity™ HPV Assay detects and identifies 14 high-risk human papillomavirus (HPV) types in a single analysis. The assay is for use in accordance with clinical guidelines and within the scope of local regulatory authorizations as part of a comprehensive approach to cervical cancer screening.

Self-collected Swab for HPV Testing

Specimen type: self-collected vaginal specimen collected with Copan FLOQSwab (Catalog No. 5E089N).

Specimen collection procedure: refer to Instructions for Use (product insert) accompanying the collection kit or [Click Here]

Specimen labelling: swab specimen holder must be clearly labelled with Name, NRIC/Fin/Passport No., Date of Birth, and Date and Time of collection.

Specimen storage: stable for up to 30 days when stored at 2-30°C after collection dry transport, but not more than 6 days exposure at 40°C.

Expected turnaround time: 3-5 working days (Urgent request not available for this test)

Factors known to significantly impact the performance of the test or the interpretation of the results:

• If concentration of blood exceeds 1% (v/v) in a vaginal self-collected sample, there is a likelihood of obtaining a false-negative HPV result.
• False negatives may occur for specimens containing >8% (v/v) mucin, >7% (w/v) Zovirax® (Acyclovir) Cream. And >8% (w/v) clindamycin vaginal cream.
• The effects of other potential variables, such as vaginal discharge, use of tampons, douching, etc. and specimen collection variables, have not been evaluated.
• The BD Onclarity HPV Assay was not evaluated in women with acetic acid, iodine, spermicide, douche, or anti-fungal medications applied within 24 hours of specimen collection.

HPV and Liquid-based Cytology (LBC) Co-testing (SurePath or ThinPrep)^#

Specimen type: BD SurePath or ThinPrep vial.

Specimen collection procedure: refer to Instructions for Use (product insert) accompanying the collection kit or [Click Here]

Specimen labelling: specimen vial must be clearly labelled with Name, NRIC/Fin/Passport No., Date of Birth, and Date and Time of collection.

Specimen storage: stable for up to 30 days when stored at 2-30°C after collection.

Expected turnaround time: 5-7 working days (Normal cases); 7-14 working days (Positive cases)

Factors known to significantly impact the performance of the test or the interpretation of the results:

• If concentration of blood exceeds 1% (v/v) in a vaginal self-collected sample, there is a likelihood of obtaining a false-negative HPV result.
• False negatives may occur for specimens containing >8% (v/v) mucin, >7% (w/v) Zovirax® (Acyclovir) Cream. And >8% (w/v) clindamycin vaginal cream.
• The effects of other potential variables, such as vaginal discharge, use of tampons, douching, etc. and specimen collection variables, have not been evaluated.
• The BD Onclarity HPV Assay was not evaluated in women with acetic acid, iodine, spermicide, douche, or anti-fungal medications applied within 24 hours of specimen collection.

^# SurePath and ThinPrep LBC tests are outsourced tests.

Genetic Testing Services

ABCA4 Single Gene Sequencing

Specimen: 2-4 mL of blood with anticoagulant EDTA

Lab method: Next generation sequencing. Our solution entails a targeted full-genomic sequencing approach that enables deep sequencing of a gene's complete genomic sequence, encompassing its enhancers, promoters, exons, shallow introns and importantly, the deep introns.

Indications for genetic testing:

1. Confirmation of clinical diagnosis
2. Carrier testing for at-risk family members
3. Genetic counseling
4. Prenatal diagnosis for known familial mutation

Autosomal recessive Stargardt disease is a juvenile-onset macular dystrophy associated with rapid central visual impairment, progressive bilateral atrophy of the foveal retinal pigment epithelium, and the frequent appearance of yellowish flecks around the macula and/or in the central and near-peripheral areas of the retina.

Urea Cycle Disorder (UCD) Panel

Specimen: 2-4 mL of blood with anticoagulant EDTA

Lab method: Next generation sequencing. The UCD panel encompasses capture probes designed for eight genes, namely ARG1, ASL, ASS1, CPS1, NAGS, OTC, SLC25A13, and SLC25A15. Our solution entails a targeted full-genomic sequencing approach that enables deep sequencing of a gene's complete genomic sequence, encompassing its enhancers, promoters, exons, shallow introns and importantly, the deep introns.

Indications for genetic testing:

1. Confirmation of clinical diagnosis
2. Carrier testing for at-risk family members
3. Genetic counseling
4. Prenatal diagnosis for known familial mutation

List of diseases covered by the UCD panel:

---

Contact us for service enquiry!